We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Costco Wholesale, The Walt Disney, AstraZeneca, O'Reilly Automotive and Restaurant Brands International
Read MoreHide Full Article
For Immediate Release
Chicago, IL – March 1, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Costco Wholesale Corp. (COST - Free Report) , The Walt Disney Co. (DIS - Free Report) , AstraZeneca PLC (AZN - Free Report) , O'Reilly Automotive, Inc. (ORLY - Free Report) and Restaurant Brands International Inc. (QSR - Free Report)
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for Costco, Walt Disney and AstraZeneca
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corp., The Walt Disney Co. and AstraZeneca PLC. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Costco's shares have outperformed the Zacks Retail - Discount Stores industry over the past year (+60.9% vs. +30.8%). A consumer defensive stock, Costco has been surviving the market turmoil pretty well.
The discount retailer's key strengths are strategic investments, a customer-centric approach, merchandise initiatives and an emphasis on membership growth. These factors have been helping it register decent sales and earnings numbers.
This outlook reflects Costco's ability to navigate the challenging operating environment, generate solid sales and register high membership renewal rates. A favorable product mix, steady store traffic, pricing power and strong liquidity position should help Costco keep outperforming. While trading at a premium to its peers, its long-term growth prospects should help the stock see solid upside.
Shares of Walt Disney have outperformed the Zacks Media Conglomerates industry over the past year (+12.8% vs. +1.2%). The company's first-quarter fiscal 2024 results reflect a solid revival in international theme park and resort businesses. Recent attractions like the Frozen theme land at Hong Kong Disneyland and Walt Disney Park in Paris, as well as the Zootopia theme land at Shanghai Disney, are expected to boost the prospects of the theme park business.
Disney's declining ad revenues, due to fewer impressions, has been a headwind for some time now. Disney+'s profitability is expected to be negatively impacted by higher investments in content, which will increase programming and production costs at Media and Entertainment Distribution.
Its leveraged balance sheet remains a concern. Disney+ is facing tough competition in the streaming market from the likes of Netflix and Amazon Prime Video.
AstraZeneca shares have gained +2.4% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +35.3%. The company's key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra and Farxiga should keep driving revenues.
AstraZeneca has also been engaged in external acquisitions and strategic collaborations to boost its pipeline, while investing in geographic areas of high growth like emerging markets. Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period.
However, AstraZeneca's diabetes franchise faces stiff competition, while pricing pressure hurts sales in the respiratory unit. Sales have slowed down in its key market, China. Estimates have gone up slightly ahead of the Q4 earnings release. The company has a positive record of earnings surprises in the recent quarters.
Other noteworthy reports we are featuring today include O'Reilly Automotive, Inc. and Restaurant Brands International Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Costco Wholesale, The Walt Disney, AstraZeneca, O'Reilly Automotive and Restaurant Brands International
For Immediate Release
Chicago, IL – March 1, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Costco Wholesale Corp. (COST - Free Report) , The Walt Disney Co. (DIS - Free Report) , AstraZeneca PLC (AZN - Free Report) , O'Reilly Automotive, Inc. (ORLY - Free Report) and Restaurant Brands International Inc. (QSR - Free Report)
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for Costco, Walt Disney and AstraZeneca
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corp., The Walt Disney Co. and AstraZeneca PLC. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Costco's shares have outperformed the Zacks Retail - Discount Stores industry over the past year (+60.9% vs. +30.8%). A consumer defensive stock, Costco has been surviving the market turmoil pretty well.
The discount retailer's key strengths are strategic investments, a customer-centric approach, merchandise initiatives and an emphasis on membership growth. These factors have been helping it register decent sales and earnings numbers.
This outlook reflects Costco's ability to navigate the challenging operating environment, generate solid sales and register high membership renewal rates. A favorable product mix, steady store traffic, pricing power and strong liquidity position should help Costco keep outperforming. While trading at a premium to its peers, its long-term growth prospects should help the stock see solid upside.
(You can read the full research report on Costco here >>>)
Shares of Walt Disney have outperformed the Zacks Media Conglomerates industry over the past year (+12.8% vs. +1.2%). The company's first-quarter fiscal 2024 results reflect a solid revival in international theme park and resort businesses. Recent attractions like the Frozen theme land at Hong Kong Disneyland and Walt Disney Park in Paris, as well as the Zootopia theme land at Shanghai Disney, are expected to boost the prospects of the theme park business.
Disney's declining ad revenues, due to fewer impressions, has been a headwind for some time now. Disney+'s profitability is expected to be negatively impacted by higher investments in content, which will increase programming and production costs at Media and Entertainment Distribution.
Its leveraged balance sheet remains a concern. Disney+ is facing tough competition in the streaming market from the likes of Netflix and Amazon Prime Video.
(You can read the full research report on Walt Disney here >>>)
AstraZeneca shares have gained +2.4% over the past year against the Zacks Large Cap Pharmaceuticals industry's gain of +35.3%. The company's key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra and Farxiga should keep driving revenues.
AstraZeneca has also been engaged in external acquisitions and strategic collaborations to boost its pipeline, while investing in geographic areas of high growth like emerging markets. Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period.
However, AstraZeneca's diabetes franchise faces stiff competition, while pricing pressure hurts sales in the respiratory unit. Sales have slowed down in its key market, China. Estimates have gone up slightly ahead of the Q4 earnings release. The company has a positive record of earnings surprises in the recent quarters.
(You can read the full research report on AstraZeneca here >>>)
Other noteworthy reports we are featuring today include O'Reilly Automotive, Inc. and Restaurant Brands International Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.